



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

August 13, 2021

Natasha Giordano  
Chief Executive Officer  
PLx Pharma Inc.  
9 Fishers Lane Suite E  
Sparta, New Jersey 07871

**Re: PLx Pharma Inc.**  
**Registration Statement on Form S-3**  
**Filed August 6, 2021**  
**File No. 333-258540**

Dear Ms. Giordano:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jordan Nimitz at 202-551-6001 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Robert Friedman, Esq.